In this context, the chemokine receptor CXCR4 has been favored to help tumor cells to settle down in the BM [48] and we recently demonstrated that CXCR4/JUNB/CK-expressing DTCs were frequently detected in the BM of early staged diagnosed BC patients and seem to identify a subgroup of patients at higher risk for relapse [10]. This evidence concerns the gene JUNB and neoplasm.